Interest and limit of a free light chain immunoassay in serum and urine for the diagnosis and the follow-up of monoclonal dysglobulinemia;Intérêt et limites des dosages sériques et urinaires des chaînes légères libres pour le diagnostic et le suivi des dysglobulinémies monoclonales

Annales de Biologie Clinique

Volumn 64, Issue 3, 2006, Pages 287-297

  Lopez, J ^a   Dauwalder, O ^a   Joly, P ^a   Dimet, I ^a   Bienvenu, J ^a   Bernon, H ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Free light chain; Freelite immunoassay; Monoclonal gammopathy; Myeloma; Non secretory myeloma

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

AGED; ARTICLE; BLOOD; CASE REPORT; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PARAPROTEINEMIA; URINE;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PARAPROTEINEMIAS;

EID: 33744955843     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Durie BG. The epidemiology of multiple myeloma. Semin Hematol 2001 ; 38 (Suppl. 3) : 1-5.
2. Solomon A. Bence-Jones proteins and light chains of immunoglobulins (first of two parts). N Engl J Med 1976 ; 294 : 17-23.
3. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantitation with urine Bence Jones protein in light chain myeloma. Clin Chem 2002 ; 48 : 655-7.
4. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001 ; 47 : 673-80.
5. Carr-Smith HD, Showell P, Bradwell AR. Antigen excess assessment of free light chain assays on the Dade-Behring BNII nephelometer. Clin Chem 2002 ; 48 : A-71 pA23.
6. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains : relative sensitivity for detection of monoclonal light chains. Clin Chem 2002 ; 48 : 1437-44.
7. Solomon A, Waldmann TA, Fahey JL, McFarlane AS. Metabolism of Bence Jones Proteins. J Clin Invest 1964 ; 43 : 103-17.
8. Nowrousian MR, Brandhorst D, Daniels R, et al. Free light-chain measurement in serum compared with immunofixation of urine in patients with multiple myeloma. Blood 2003 ; 102 : A5197.
9. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003 ; 361 : 489-91.
10. Mead GP, Carr-Smith H, Drayson M, Bradwell AR. Serum free light chain assays provide improved monitoring of myeloma therapy. Br J Haematol 2003 ; 121 (Suppl. 1) : 69.
11. Solling K, Nielsen JL, Soiling J, Ellegaard J. Free light chains of immunoglobulins in serum from patients with leukaemias and multiple myeloma. Scand J Haematol 1982 ; 28 : 309-18.
12. Bradwell AR, Mead GP, Drayson MT, Carr-Smith HD. Serum immunoglobulin free light chain measusrement in intact immunoglobulin multiple myeloma. Blood 2002 ; 100 : 373.
13. Sirohi B, Powles R, Kulkarni S, et al. Serum free light chain assessment in myeloma patients who are in complete remission (CR) by immunofixation predicts early relapse. Blood 2003 ; 102 : A5195.
14. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001 ; 97 : 2900-2.
15. Mead GP, Stubbs PD, Carr-Smith HD, Drew R, Drayson MT, Bradwell AR. Nephelometric measurement of serum free light chains in nonsecretory myeloma. Clin Chem 2002 ; 48 (Suppl.) : A23-A70.
16. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003 ; 122 : 78-84.
17. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002 ; 20 : 1625-34.
18. Rajkumar SV, Kyle RA, Therneau TM, Bradwell AR, Melton J, Katzmann JA. Presence of monoclonal free light chains in serum predicts risk of progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2003 ; 102 : A5234.
19. Chapuis-Cellier C, Chazaud A, Foray V, Troncy J. Apparent discrepancies in the quantification of free light chains in serum of patients presenting with a monoclonal gammopathy. Haematologica 2005 ; 90 (Suppl. 1) : 109.